A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 78 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Returning to Dental Care August 24, 2020 Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 Cross-Border Network of European Specialists Provides New Treatment Options For Women... June 17, 2024 What Are Patient-Reported Outcomes and Why Are They Important in Cancer... June 29, 2023 Load more HOT NEWS ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June FDA Approves Blinatumomab as Consolidation for CD19-positive Philadelphia Chromosome-negative B-Cell Precursor... The Winter Solstice Triple Negative Breast Cancer May Not Be Categorized As ‘Breast’ Cancer...
